Gyl Financial Synergies, LLC Biogen Inc. Transaction History

Gyl Financial Synergies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 01, 2021	SELL	$282.99 - $369.05 $175,453 - $228,811	-620 Closed	0 $0
Q2 2021 Aug 02, 2021	BUY	$259.0 - $414.71 $160,580 - $257,120	620 New	620 $215,000
Q4 2020 Feb 02, 2021	SELL	$236.26 - $355.63 $172,469 - $259,609	-730 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$264.77 - $305.71 $193,282 - $223,168	730 New	730 $207,000
Q2 2020 Aug 04, 2020	SELL	$258.66 - $342.55 $257,366 - $340,837	-995 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$220.06 - $304.07 $25,526 - $35,272	116 Added 13.2%	995 $295,000
Q2 2019 Aug 09, 2019	SELL	$219.29 - $241.72 $438 - $483	-2 Reduced 0.23%	879 $206,000
Q1 2019 May 21, 2019	SELL	$216.71 - $338.96 $19,287 - $30,167	-89 Reduced 9.18%	881 $208,000
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $17,986 - $28,133	83 Added 9.36%	970 $229,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $247,029 - $312,889	887 New	887 $267,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Gyl Financial Synergies, LLC, based on Form 13F filings with the SEC.

Stay updated on Gyl Financial Synergies, LLC with notifications on news.